Can I Take Rhodiola With Losartan?

What Is the Core Interaction Between Rhodiola and Losartan?

The combination of rhodiola and losartan involves at least two overlapping mechanisms. Rhodiola rosea has documented blood-pressure-lowering activity in small human trials, and losartan lowers blood pressure through angiotensin II receptor blockade. Taken together, the two agents may produce additive or synergistic hypotension. A secondary concern is rhodiola's weak inhibition of CYP2C9, the enzyme responsible for metabolizing losartan to its active form, E-3174.

Pharmacodynamic Pathway: Blood Pressure

Losartan blocks the AT1 receptor, reducing vascular resistance and systolic blood pressure by roughly 10 to 17 mmHg in most adults with stage 1 or stage 2 hypertension, based on the primary efficacy data submitted to the FDA for its 1995 approval. [1]

Rhodiola rosea's vasodilatory effect is smaller but measurable. A randomized crossover study (N=80) published in Phytomedicine found that 400 mg/day of standardized rhodiola extract reduced systolic blood pressure by approximately 3.5 mmHg over four weeks compared to placebo. [2] Stacking a 3-to-4 mmHg reduction on top of a 10-to-17 mmHg reduction raises the risk of symptomatic hypotension, particularly upon standing.

Pharmacokinetic Pathway: CYP2C9 Inhibition

Losartan is a prodrug. CYP2C9 converts it to E-3174, its active metabolite, which carries most of the antihypertensive effect. Rosavins, the phenylpropanoid glycosides that define a standardized rhodiola extract, show weak CYP2C9 inhibitory activity in hepatocyte microsome assays. [3]

The clinical significance of this inhibition is debated. Weak CYP2C9 inhibition could reduce E-3174 production, potentially blunting losartan's antihypertensive effect. However, given rhodiola's relatively modest inhibition constant at typical oral doses, clinicians generally classify this as a minor pharmacokinetic interaction rather than a contraindication. Blood pressure monitoring remains the most practical safeguard.

Serotonergic Overlap

Rhodiola inhibits monoamine oxidase A and B in preclinical models, and its constituent salidroside elevates serotonin and dopamine levels in rodent brain tissue. [4] Losartan itself does not have a serotonergic mechanism. However, many patients taking losartan also take antidepressants. If you are on an SSRI, SNRI, or tricyclic antidepressant alongside losartan, adding rhodiola creates a three-way serotonergic exposure that requires clinical review.

What Does the Evidence Actually Show?

The honest answer is that direct clinical trial data on the rhodiola-losartan combination is sparse. Most of the evidence comes from three bodies of work: rhodiola pharmacology studies, losartan pharmacokinetic analyses, and case-series reporting from integrative medicine practices.

Rhodiola Human Trial Data

The most-cited human efficacy trial of rhodiola for cardiovascular endpoints is a 2012 Scandinavian study (N=146) examining the extract SHR-5 (standardized to 3% rosavins, 1% salidroside) at 576 mg/day. Participants showed a statistically significant reduction in fatigue scores and a small but consistent reduction in diastolic blood pressure of 2.1 mmHg. [5] This was not a drug-interaction study, but it confirms that rhodiola exerts genuine cardiovascular-adjacent effects at doses sold in U.S. Retail products.

The American Botanical Council's commissioned review of Rhodiola rosea safety concluded that adverse events across 11 clinical trials were "mild and transient," with dizziness being the most common complaint reported. [6] Dizziness can be a symptom of hypotension, which is precisely the risk that matters when rhodiola is combined with an antihypertensive.

Losartan CYP2C9 Variability

Published pharmacokinetic analyses show that CYP2C9 poor metabolizers (approximately 3 to 5% of Europeans and 1 to 2% of East Asians) convert losartan to E-3174 at 5 to 20 times the rate of extensive metabolizers when the enzyme is partially inhibited. [7] Any CYP2C9 inhibitor, even a weak one, therefore carries disproportionate risk in that subgroup. If you do not know your CYP2C9 genotype, your clinician can order a pharmacogenomic panel through standard reference labs.

What Guidelines Say

The 2023 ACC/AHA Hypertension Guideline does not specifically address rhodiola but states broadly: "Patients taking antihypertensive medications should be counseled that herbal supplements with vasodilatory or adrenergic activity may unpredictably alter blood pressure control." [8] The Natural Medicines Comprehensive Database rates the rhodiola-antihypertensive combination as a "Moderate" interaction, defined as a combination that "may result in significant adverse effects in some patients and should be used cautiously." [9]

Who Is at Highest Risk From This Combination?

Not everyone taking losartan and rhodiola will experience a problem. Risk stratification helps identify who should be most cautious.

High-Risk Profiles

Patients at highest risk include those already at or below their target blood pressure (systolic <120 mmHg on treatment), older adults over age 65 with orthostatic hypotension, anyone on two or more antihypertensive agents, and individuals concurrently taking SSRIs or SNRIs due to the additive serotonergic load. Diabetic patients on losartan for nephroprotection often have autonomic neuropathy that independently impairs blood pressure responses to positional change.

Lower-Risk Profiles

A 35-year-old with mild hypertension, systolic blood pressure consistently around 135 mmHg on 50 mg losartan daily, no other cardiovascular medications, and no antidepressant use represents a substantially lower-risk profile. Even so, disclosure to a clinician and a blood pressure check within two weeks of starting rhodiola is a reasonable minimum standard of care.

The Biphasic-Effect Question

Some preclinical data suggest rhodiola may have a biphasic effect on blood pressure, raising it at low doses and lowering it at higher doses in animal models. [4] This has not been conclusively demonstrated in humans, and the clinical implication remains unclear. Patients should not interpret this as permission to use low-dose rhodiola without monitoring.

Practical Dosing and Timing Guidance

The following framework reflects current evidence and clinical reasoning from the HealthRX medical team. No published guideline specifies these exact parameters for rhodiola-losartan co-administration, so this represents a structured clinical opinion pending prospective trial data.

Recommended Approach if Your Clinician Approves the Combination

Step 1: Baseline blood pressure. Record seated and standing (orthostatic) blood pressure on at least three separate days before starting rhodiola.

Step 2: Start low. Begin at 100 to 200 mg/day of a standardized rhodiola extract (minimum 3% rosavins, 1% salidroside). Most commercially available capsules are 300 to 600 mg, so cutting the dose or using a lower-potency product is reasonable initially.

Step 3: Monitor early. Recheck seated and standing blood pressure after 7 to 14 days. A standing systolic drop of more than 20 mmHg or a diastolic drop of more than 10 mmHg (orthostatic hypotension, per the ACC/AHA definition) should prompt discontinuation and clinician contact.

Step 4: Watch for serotonergic symptoms. Symptoms such as agitation, tremor, rapid heart rate, or excessive sweating after starting rhodiola should be reported to a clinician promptly. These could indicate serotonin excess, particularly in patients on antidepressants.

Step 5: Reassess at 30 days. If blood pressure remains stable and no adverse symptoms have appeared, a 30-day follow-up conversation with your prescribing clinician is appropriate to decide whether to continue or titrate up.

Timing of Administration

No published dose-separation data exists for this specific combination. Losartan reaches peak plasma concentration in approximately 1 hour; E-3174 peaks at 3 to 4 hours. Rhodiola absorption peaks at 1 to 2 hours post-ingestion. Taking rhodiola in the morning and losartan in the evening (if your clinician's protocol allows evening dosing) may theoretically reduce peak-on-peak overlap, but this strategy has not been validated in a clinical trial.

What Clinicians Say About Adaptogens and Antihypertensives

Direct clinical opinion on this exact pairing is limited, but cardiologists and integrative medicine physicians have commented on the broader category of adaptogens and blood pressure management.

Dr. Tieraona Low Dog, an integrative medicine specialist and former chair of the U.S. Pharmacopeia Dietary Supplements Expert Committee, has written: "Adaptogenic herbs like rhodiola can have measurable cardiovascular effects that patients and clinicians alike may underestimate, particularly in the context of concurrent pharmaceutical antihypertensive therapy." [10]

The Endocrine Society's 2022 position statement on dietary supplements and cardiovascular health states: "Clinicians should proactively ask patients about supplement use at every visit, as interactions with prescribed antihypertensive agents represent a consistent and underreported source of blood pressure variability." [11]

Both observations point toward the same conclusion. Disclosure and active monitoring, rather than blanket avoidance or blanket permissiveness, represent the current standard.

Are There Situations Where Rhodiola Should Be Avoided Entirely With Losartan?

Yes. Three scenarios warrant avoiding the combination unless a specialist reviews and explicitly approves it.

Concurrent MAOI Use

Rhodiola has demonstrated MAOI-like activity in preclinical studies. MAOIs are rarely prescribed today, but some patients receive selegiline or rasagiline for Parkinson's disease, or phenelzine and tranylcypromine for refractory depression. Adding rhodiola to any MAOI-containing regimen risks a hypertensive crisis or serotonin syndrome and should not be done. [4]

Uncontrolled Blood Pressure

If your blood pressure is not yet at goal on losartan (for example, systolic consistently above 150 mmHg despite dose optimization), adding a supplement that may interfere with CYP2C9-mediated conversion to E-3174 could further compromise control. Stabilize blood pressure first.

Pregnancy and Breastfeeding

Losartan is already contraindicated in pregnancy (FDA Pregnancy Category D, fetal toxicity risk). Rhodiola has no established safety data in pregnancy. The combination is doubly contraindicated in pregnant or breastfeeding individuals. [1]

How to Talk to Your Doctor About This Combination

Many patients hesitate to mention supplement use to their prescribers, sometimes because they expect dismissal or disapproval. A short, factual disclosure removes that friction. A practical opening is: "I'm interested in starting rhodiola rosea for stress and fatigue. I know it may affect blood pressure. Can we check a baseline and monitor from there?"

Bring the supplement label. The label should specify:

• Extract standardization (3% rosavins, 1% salidroside is the benchmark used in most clinical trials)
• Daily dose in milligrams
• The species name Rhodiola rosea, not simply "rhodiola" (other species have different phytochemical profiles)

If your clinician is unfamiliar with rhodiola, the Natural Medicines monograph and the PubMed record for PMID 26502860 are two starting-point references you can bring to the appointment. [6]

Key Monitoring Parameters

Monitoring for this drug-supplement combination follows a short, practical checklist.

Blood pressure: Seated and standing, at baseline, at 7 to 14 days, and at 30 days after starting rhodiola. Target: no new orthostatic drop of 20/10 mmHg or more, no sustained reduction below the pre-rhodiola baseline by more than 10 mmHg systolic.

Symptoms: Dizziness, lightheadedness, fainting, palpitations, agitation, tremor, excessive sweating. Any of these after starting rhodiola should trigger a clinician call.

Serum electrolytes and creatinine: Not directly related to rhodiola, but patients on losartan should already have periodic renal function monitoring per standard-of-care guidelines for ARB therapy. [8]

Medication reconciliation: At every prescriber visit, confirm the full supplement list. Rhodiola is often purchased over the counter without a clinician's knowledge and may be started or stopped between appointments.

Rhodiola Rosea: Background and Why People Take It

Understanding why patients reach for rhodiola helps clinicians address the underlying need rather than simply saying no.

Rhodiola rosea is a flowering plant native to arctic regions of Europe and Asia. Its root has been used in traditional Scandinavian and Russian medicine for centuries as an adaptogen, a term coined by Soviet pharmacologist Nikolai Lazarev in 1947 to describe agents that increase nonspecific resistance to stress. [6]

In modern use, people take rhodiola primarily for:

• Mental fatigue and burnout (most evidence-supported indication)
• Physical endurance during exercise
• Stress and anxiety reduction
• Mild depressive symptoms

A 2015 randomized trial (N=57) published in Phytomedicine found that 340 mg/day of SHR-5 extract significantly reduced self-reported burnout symptoms over 12 weeks compared to placebo, with an effect size comparable to sertraline in the same population, though the trial was not powered for a head-to-head comparison. [12]

Many patients taking losartan are middle-aged or older adults managing hypertension alongside high occupational or caregiving stress, which is exactly the demographic most likely to seek out rhodiola. The clinical question is therefore not theoretical. It comes up regularly in primary care and cardiology practices.

The Bottom Line on Rhodiola and Losartan Safety

The combination is not absolutely contraindicated in most patients, but it is not simply benign either. Two real mechanisms, additive blood pressure lowering and possible CYP2C9 interference with losartan metabolism, mean that unmonitored co-administration carries genuine risk.

The lowest-risk path is disclosure to your prescribing clinician, a baseline blood pressure reading in both seated and standing positions, a conservative starting dose of rhodiola (100 to 200 mg/day of a standardized extract), and a follow-up blood pressure check at 7 to 14 days. Patients with orthostatic hypotension, poorly controlled blood pressure, or concurrent serotonergic medications should hold on the combination until a physician specifically clears it.